Noromby
Enoxaparin sodium biosimilar developed by Juno Pharma Canada. Reference product Clexane (Lovenox in the United States).
Brands by market: Noromby (Canada) · Commercial partner or holder: Juno Pharma Canada · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCOct 2020approved
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Noromby
Noromby is Juno Pharma's enoxaparin for Canada, approved in October 2020, one of five enoxaparins that Health Canada treats as biosimilars. It also comes in a higher-strength form.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Noromby
Health CanadaApprovedBrand
Noromby
Holder or applicant
Juno Pharma Canada INC.
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Oct 2020
Application or permission
DIN 02506459, 02506467, 02506475, 02506483, 02506491, 02506505, 02506513
Presentations
100, 30, 40, 60, 80 mg; 120, 150 mg
Remarks
Also Noromby Hp.
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Noromby holds an approval, these are the other enoxaparin sodium biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| HC | 4 | Baxter (Axberi), Fresenius Kabi (Elonox), Sandoz (Inclunox), Techdow (Inhixa) |
Chronology
- HCOct 2020Notice of Compliance, Health Canada
Sources
Planning enoxaparin sodium biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.